![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, September 29, 2020 10:14:59 AM
Organicell Regenerative Medicine's Zofin nabs accelerated review in U.S. to treat COVID-19 patients
Sep. 29, 2020 10:11 AM ETOrganicell Regenerative Medicine, Inc. (BPSR)By: Meghavi Singh, SA News Editor
The FDA grants Zofin for the treatment of COVID-19 to Organicell Regenerative Medicine (OTCPK:BPSR -3.3%).
Zofin is an acellular biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs, without the addition or combination of any other substance or diluent.
Alongside Convalescent Plasma, Zofin is the first reported acellular therapy under FDA’s approved expanded access program.
A 6 subject will be treated under emergency IND to evaluate significant improvement after being treated with Zofin.
The company will commence Phase I/II placebo controlled clinical trial and is in the process of recruit moderate to severe COVID-19 patients to evaluate the safety and potential efficacy of Zofin
Recent ZEOX News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 06/14/2024 08:15:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 08:05:15 PM
Glidelogic Corp. Announces Revolutionary AI-Generated Content Copyright Protection Solution • GDLG • Jul 26, 2024 12:30 PM
Southern Silver Files NI43-101 Technical Report for its Updated Preliminary Economic Assessment for the Cerro Las Minitas Project • SSV • Jul 25, 2024 8:00 AM
Greenlite Ventures Completes Agreement with No Limit Technology • GRNL • Jul 19, 2024 10:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • NBRI • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM